Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Paula Rodriguez-Otero

Showing results (31-40 of 78) with videos related to

Pageof 8
Sort By:
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|January 24, 2009
Epigenetic regulation of microRNAs in acute lymphoblastic leukemiaJose Roman-Gomez, Xabier Agirre, Antonio Jiménez-Velasco, et al.
British Journal of Haematology|November 20, 2020
Subcutaneous daratumumab plus standard treatment regimens in patients with multiple myeloma across lines of therapy (PLEIADES): an open-label Phase II studyAjai Chari, Paula Rodriguez-Otero, Helen McCarthy, et al.
British Journal of Haematology|October 21, 2021
Patient-reported outcomes in relapsed/refractory multiple myeloma treated with melflufen plus dexamethasone: analyses from the Phase II HORIZON studyAlessandra Larocca, Xavier Leleu, Cyrille Touzeau, et al.
Journal of Medical Economics|February 17, 2026
Indirect treatment comparison of DVRd plus DR maintenance (PERSEUS study) versus DVTd or VTd with or without lenalidomide maintenance in transplant-eligible patients with previously untreated multiple myelomaMeletios A Dimopoulos, Mario Boccadoro, Hermann Einsele, et al.
Leukemia|June 14, 2023
Efficacy and safety of isatuximab plus bortezomib, lenalidomide, and dexamethasone in patients with newly diagnosed multiple myeloma ineligible/with no immediate intent for autologous stem cell transplantationEnrique M Ocio, Aurore Perrot, Pierre Bories, et al.
Blood Cancer Journal|July 10, 2024
Immune dysfunction prior to and during vaccination in multiple myeloma: a case study based on COVID-19Esperanza Martín-Sánchez, Luis-Esteban Tamariz-Amador, Camila Guerrero, et al.
The New England Journal of Medicine|February 10, 2023
Ide-cel or Standard Regimens in Relapsed and Refractory Multiple MyelomaPaula Rodriguez-Otero, Sikander Ailawadhi, Bertrand Arnulf, et al.
Leukemia|January 7, 2026
Alnuctamab, a bivalent B-cell maturation antigen-targeting T cell engager for patients with relapsed or refractory multiple myeloma: results from a phase 1, first-in-human studyNoffar Bar, Thomas Martin, Craig C Hofmeister, et al.
Blood Cancer Journal|December 15, 2021
Immune biomarkers to predict SARS-CoV-2 vaccine effectiveness in patients with hematological malignanciesLuis-Esteban Tamariz-Amador, Anna Martina Battaglia, Catarina Maia, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|December 9, 2020
Melflufen and Dexamethasone in Heavily Pretreated Relapsed and Refractory Multiple MyelomaPaul G Richardson, Albert Oriol, Alessandra Larocca, et al.
Pageof 8

Showing results (31-40 of 78) with videos related to

Sort By:
Pageof 8
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|January 24, 2009
Epigenetic regulation of microRNAs in acute lymphoblastic leukemiaJose Roman-Gomez, Xabier Agirre, Antonio Jiménez-Velasco, et al.
British Journal of Haematology|November 20, 2020
Subcutaneous daratumumab plus standard treatment regimens in patients with multiple myeloma across lines of therapy (PLEIADES): an open-label Phase II studyAjai Chari, Paula Rodriguez-Otero, Helen McCarthy, et al.
British Journal of Haematology|October 21, 2021
Patient-reported outcomes in relapsed/refractory multiple myeloma treated with melflufen plus dexamethasone: analyses from the Phase II HORIZON studyAlessandra Larocca, Xavier Leleu, Cyrille Touzeau, et al.
Journal of Medical Economics|February 17, 2026
Indirect treatment comparison of DVRd plus DR maintenance (PERSEUS study) versus DVTd or VTd with or without lenalidomide maintenance in transplant-eligible patients with previously untreated multiple myelomaMeletios A Dimopoulos, Mario Boccadoro, Hermann Einsele, et al.
Leukemia|June 14, 2023
Efficacy and safety of isatuximab plus bortezomib, lenalidomide, and dexamethasone in patients with newly diagnosed multiple myeloma ineligible/with no immediate intent for autologous stem cell transplantationEnrique M Ocio, Aurore Perrot, Pierre Bories, et al.
Blood Cancer Journal|July 10, 2024
Immune dysfunction prior to and during vaccination in multiple myeloma: a case study based on COVID-19Esperanza Martín-Sánchez, Luis-Esteban Tamariz-Amador, Camila Guerrero, et al.
The New England Journal of Medicine|February 10, 2023
Ide-cel or Standard Regimens in Relapsed and Refractory Multiple MyelomaPaula Rodriguez-Otero, Sikander Ailawadhi, Bertrand Arnulf, et al.
Leukemia|January 7, 2026
Alnuctamab, a bivalent B-cell maturation antigen-targeting T cell engager for patients with relapsed or refractory multiple myeloma: results from a phase 1, first-in-human studyNoffar Bar, Thomas Martin, Craig C Hofmeister, et al.
Blood Cancer Journal|December 15, 2021
Immune biomarkers to predict SARS-CoV-2 vaccine effectiveness in patients with hematological malignanciesLuis-Esteban Tamariz-Amador, Anna Martina Battaglia, Catarina Maia, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|December 9, 2020
Melflufen and Dexamethasone in Heavily Pretreated Relapsed and Refractory Multiple MyelomaPaul G Richardson, Albert Oriol, Alessandra Larocca, et al.
Pageof 8